Third-Line Therapy After R2 Failure in Relapsed/Refractory Follicular Lymphoma
For third-line therapy after R2 failure in relapsed/refractory follicular lymphoma, you should use CD3×CD20 bispecific antibodies (epcoritamab or mosunetuzumab) or CD19-directed CAR T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel), with bispecific antibodies being the preferred initial approach due to their off-the-shelf availability and favorable safety profile. 1
Primary Recommendation Framework
The 2025 NCCN Guidelines explicitly state that after ≥2 prior systemic therapies (which includes your R2 regimen), approved options include:
- CD3×CD20 bispecific antibodies: Mosunetuzumab and epcoritamab 1
- CD19-directed CAR T-cell therapies: Axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel 1
- BTK inhibitor combination: Zanubrutinib + obinutuzumab 1
Why Bispecific Antibodies First
Start with bispecific antibodies (epcoritamab or mosunetuzumab) as your default third-line choice because they offer:
- Immediate availability without the manufacturing delay required for CAR T-cells
- Subcutaneous administration (epcoritamab) or outpatient infusion (mosunetuzumab)
- Manageable cytokine release syndrome (CRS) that is predominantly grade 1-2 1
- No need for lymphodepleting chemotherapy
- Preservation of CAR T-cell therapy as a subsequent option if needed
Alternative Considerations Based on Clinical Context
When to Consider CAR T-Cell Therapy in Third Line
Reserve CAR T-cell therapy for third-line if the patient has:
- Early progression after R2 (particularly if <12 months duration of response)
- High-risk features such as POD24 (progression within 24 months of initial diagnosis) 1
- Young age with good performance status where you want the most definitive therapy
- Transformed disease (though this technically changes the diagnosis)
The 2021 ESMO guidelines note that CAR T-cell therapy was historically reserved for transformed FL due to toxicities, but this landscape has evolved with newer approvals 2.
Novel Triplet Combinations
The 2025 NCCN Guidelines highlight tafasitamab + lenalidomide + rituximab as an emerging option based on the phase III inMIND study, which showed significantly improved PFS compared to R2 alone 1. However, this is positioned as an enhancement of R2 rather than a post-R2 option.
Similarly, loncastuximab tesirine + rituximab (a CD19-directed antibody-drug conjugate) demonstrates efficacy in relapsed/refractory FL 1, though data are more limited.
Practical Implementation Algorithm
Step 1: Confirm true R2 failure
- Obtain repeat biopsy to exclude histologic transformation 2
- Document timing and depth of response to R2
Step 2: Assess patient fitness and disease characteristics
- Performance status (ECOG 0-2 preferred for intensive therapies)
- Comorbidities affecting treatment tolerance
- Disease burden and pace of progression
- Prior response duration to R2
Step 3: Select therapy
For most patients: Initiate bispecific antibody therapy
- Epcoritamab: Subcutaneous, step-up dosing (0.16 mg → 0.8 mg → 48 mg full doses), manageable CRS profile 3, 4
- Mosunetuzumab: Intravenous, similar step-up approach 1
For younger, fit patients with aggressive features: Consider proceeding directly to CAR T-cell therapy
For elderly/frail patients: Consider zanubrutinib + obinutuzumab as a less intensive option 1
Critical Safety Considerations
Cytokine Release Syndrome Management
With bispecific antibodies, CRS is expected but manageable:
- Predominantly grade 1 (38%) and grade 2 (11%) with epcoritamab 3
- Step-up dosing strategy specifically designed to mitigate severe CRS
- Hospitalization for first full dose recommended
- Have tocilizumab readily available
- All CRS events in trials resolved without treatment discontinuation 3
Infection Risk
Implement aggressive prophylaxis:
- Anti-pneumocystis prophylaxis (trimethoprim-sulfamethoxazole or alternative)
- Antiviral prophylaxis (acyclovir/valacyclovir)
- CMV monitoring if using certain agents 2
- COVID-19 was a common adverse event in trials (59% with epcoritamab + R2) 3
Hepatitis B Reactivation
Screen all patients for HBV before initiating any rituximab-containing or CD20-directed therapy, with prophylactic antiviral medication for positive serology 5.
Emerging Evidence and Future Directions
The EPCORE FL-1 trial (2026) demonstrated that epcoritamab + R2 versus R2 alone achieved 95% ORR versus 79%, with significantly longer PFS (HR 0.21, p<0.0001) 4. While this positions epcoritamab + R2 as a potential second-line standard, it reinforces the potency of bispecific antibodies in the relapsed setting.
For patients who have already failed R2, the standalone bispecific antibody data remain most relevant for third-line decision-making.
Common Pitfalls to Avoid
- Don't delay biopsy at relapse: Transformation occurs in 2-3% of FL patients annually and fundamentally changes management
- Don't underestimate CRS with first bispecific dose: Ensure appropriate monitoring and supportive care infrastructure
- Don't forget fertility preservation discussions: Particularly relevant if considering subsequent stem cell transplant
- Don't use rituximab monotherapy in R2-refractory disease: This represents double rituximab failure and is unlikely to be effective 2
When Stem Cell Transplant Enters Consideration
The 2021 ESMO guidelines recommend considering autologous stem cell transplant (ASCT) for patients with brief first remissions after rituximab-containing regimens 2. However, in the modern era with effective bispecific antibodies and CAR T-cells, ASCT is increasingly reserved for:
- Patients who fail both bispecific antibodies and CAR T-cell therapy
- Selected younger patients with very high-risk features
- Bridge to allogeneic transplant in exceptional circumstances 2
Allogeneic stem cell transplant remains a consideration only for highly selected younger patients with later relapses and high-risk profiles or those who have failed multiple lines including cellular therapies 2.